Peloton PTON and why you should avoid Peloton PTON stock

MADRID — Head­ed in­to the year’s sec­ond-largest can­cer con­fer­ence, ex­pec­ta­tions were a lit­tle sub­dued for As­traZeneca’s next big bet on an­ti­body-drug con­ju­gates. The phar­ma’s Dai­ichi

SAN DIEGO — Fac­ing an ex­is­ten­tial mo­ment in how drugs are de­vel­oped and sold, biotech’s key lob­by­ing group has en­trust­ed a new leader, who is